General Provisions - The management system for the shares held by the board of directors and senior management of Xianle Health Technology Co., Ltd. is established to regulate shareholding and changes in accordance with relevant laws and regulations [1][2] - This system applies to the board of directors, senior management, and other specified individuals or organizations holding and trading the company's stocks and derivatives [1] Holding and Reporting Requirements - Directors and senior management must report their shareholdings and any changes to the Shenzhen Stock Exchange (SZSE) in a timely manner, ensuring the information is true, accurate, timely, and complete [2][3] - Personal and family identity information must be reported to SZSE within specified timeframes, including when new directors are appointed or when there are changes in personal information [2][3] Restrictions on Trading Company Shares - Directors and senior management must notify the board secretary in writing of their trading plans before buying or selling company shares, and the secretary must verify compliance with laws and regulations [3][4] - The annual transferable share limit for directors and senior management is calculated at 25% of the shares held as of the last trading day of the previous year [4][5] Lock-up and Transfer Conditions - Shares held by directors and senior management are subject to lock-up conditions, and the release of these conditions must be applied for through the appropriate channels [5][6] - Directors and senior management are prohibited from transferring shares within six months of leaving their positions and must adhere to specific transfer limits during their tenure [5][6] Information Disclosure - Any reduction in shareholding must be reported to SZSE 15 trading days prior to the first sale, and updates must be provided if significant company events occur during the reduction period [8][9] - The board secretary is responsible for managing the identity and shareholding data of directors and senior management, ensuring compliance with reporting requirements [9][10] Final Provisions - The system is subject to modification and will take effect upon approval by the board of directors [10]

Core Viewpoint - The company establishes an investor relations management system to enhance communication with investors, protect their rights, and improve corporate governance and transparency [1][2][3]. Group 1: Principles and Objectives of Investor Relations Management - The investor relations management should adhere to principles of fairness, justice, and openness, providing accurate and complete information about the company's actual situation [2][3]. - The primary objectives include enhancing investor understanding and recognition of the company, improving governance structure, and ensuring all investors enjoy their rights equally [3][4]. Group 2: Communication Methods and Activities - The company should utilize various channels for timely and in-depth communication with investors, including designated information disclosure platforms [4][5]. - Activities include organizing shareholder meetings, maintaining a company website, and conducting analyst meetings and roadshows to engage with investors [5][6][7]. Group 3: Responsibilities and Management - The chairman of the board is the primary responsible person for investor relations, with the board secretary overseeing daily operations [11][12]. - The board office is tasked with managing investor relations and ensuring compliance with relevant laws and regulations [11][12]. Group 4: Information Disclosure and Confidentiality - The company must avoid disclosing any undisclosed significant information during investor relations activities and must promptly announce any leaks [2][4]. - All disclosed information must be published on designated platforms to ensure transparency and compliance with legal requirements [4][5].

Core Viewpoint - The independent director system of Xianle Health Technology Co., Ltd. aims to enhance corporate governance, ensure the independence of directors, and protect the rights of all shareholders, especially minority shareholders [1][2]. Group 1: General Principles - The company establishes this system to improve its governance structure and ensure independent directors fulfill their responsibilities [1]. - Independent directors must constitute at least one-third of the board, with at least one being a professional accountant [1][2]. - Independent directors are prohibited from holding other positions within the company and must not have any direct or indirect interests that could affect their independent judgment [2][3]. Group 2: Qualifications and Appointment - Independent directors must possess independence and cannot be influenced by major shareholders or related parties [2][4]. - Specific individuals are disqualified from serving as independent directors, including those with significant shareholdings or familial ties to major shareholders [2][4][5]. - The board and shareholders holding over 1% of shares can propose independent director candidates, who must be approved by the shareholders' meeting [5][6]. Group 3: Responsibilities and Duties - Independent directors are responsible for participating in board decisions, supervising potential conflicts of interest, and providing professional advice [9][10]. - They have special rights, including the ability to hire external consultants and propose meetings [9][10]. - Independent directors must attend board meetings and provide written opinions if unable to attend [10][11]. Group 4: Performance and Reporting - Independent directors are required to submit annual reports detailing their attendance, participation in committees, and communication with shareholders [15][16]. - They must report any situations that may affect their independence and can resign if necessary [16][17]. - The company must ensure independent directors have sufficient time and resources to fulfill their duties effectively [17][18]. Group 5: Support and Communication - The company is obligated to provide necessary support and information to independent directors to facilitate their work [17][18]. - Independent directors should have direct communication channels with shareholders and be able to report issues to regulatory bodies if necessary [19][20].

Core Points - The article outlines the information disclosure deferral and exemption management system of Xianle Health Technology Co., Ltd, ensuring compliance with relevant laws and regulations [1][2][3] - The company is required to implement internal review procedures before determining whether to defer or exempt information disclosure [2][3] - The system emphasizes the importance of confidentiality regarding state secrets and commercial secrets, prohibiting any form of disclosure that could lead to competitive disadvantages or legal violations [3][4][5] Summary by Sections General Principles - The system is established to regulate the deferral and exemption of information disclosure, ensuring compliance with laws such as the Company Law and Securities Law [1] - The company must adhere to the Shenzhen Stock Exchange's rules regarding information disclosure deferral and exemption [1][2] Scope of Deferral and Exemption - The company must prudently assess whether information qualifies for deferral or exemption based on established criteria [2][3] - Evidence must be provided to justify any new deferral or exemption requests post-initial public offering [2][3] Management Procedures - A written application must be submitted to the board office for any deferral or exemption, detailing the reasons and supporting evidence [4][5] - The board office is responsible for reviewing applications and ensuring compliance with the established criteria [5][6] - Confidentiality commitments must be obtained from all individuals aware of the deferred or exempt information [6][7] Additional Provisions - The company must monitor and report on the status of deferred or exempt disclosures, especially if there are rumors or leaks [6][7] - The system is subject to revision and interpretation by the board of directors, and it becomes effective upon board approval [7][8]

General Principles - The rules are established to ensure the smooth conduct of shareholder meetings, enhance efficiency, and protect shareholders' rights [1][2] - The shareholder meeting is the company's authority body, exercising various powers including electing directors, approving reports, and making decisions on capital changes [1][2] Shareholder Meeting Procedures - The company must notify shareholders of the meeting at least 20 days in advance for annual meetings and 15 days for temporary meetings [4][5] - Shareholders can appoint proxies to attend meetings, and the qualifications of attendees must be verified [5][6] Legal Opinions and Compliance - A lawyer must provide legal opinions on the legality of the meeting's procedures, attendee qualifications, and voting results [3][6] Meeting Types and Notifications - Annual meetings must be held within six months after the end of the fiscal year, while temporary meetings can be called as needed [4][8] - Notifications must include meeting details, agenda items, and the rights of shareholders to attend and vote [4][5] Proposal and Voting Procedures - Proposals must be clearly defined and submitted in writing, with specific details disclosed to shareholders [20][21] - Voting can be conducted through various methods, including in-person and online, with specific rules for counting votes [26][27] Decision-Making and Resolutions - Resolutions can be ordinary or special, with different thresholds for approval: ordinary resolutions require a simple majority, while special resolutions require a two-thirds majority [22][24] - Certain significant matters, such as amendments to the articles of association or major asset transactions, require special resolutions [24][25] Meeting Records and Documentation - Meeting records must be maintained, detailing the time, location, attendees, and outcomes of each proposal [57][58] - The company must ensure that resolutions are announced promptly and include detailed voting results [55][56] Conduct and Discipline - The company must maintain order during meetings and can remove individuals who disrupt proceedings [63][64] - The rules are binding and must be followed by all participants, ensuring the integrity of the shareholder meeting process [30][66]

Core Viewpoint - The legal opinion letter issued by Guangdong Xinda Law Firm confirms that the adjustments to the 2023 and 2025 restricted stock incentive plans of Xianle Health Technology Co., Ltd. have obtained the necessary approvals and comply with relevant laws and regulations [1][14][20]. Group 1: 2023 Restricted Stock Incentive Plan - The 2023 incentive plan has undergone adjustments due to the company's capital reserve conversion and stock dividend distribution, affecting the repurchase price and quantity of restricted stocks [14][15]. - The initial grant price for the restricted stocks was adjusted from 9.78 yuan to 7.52 yuan per share, and the total number of restricted stocks granted was adjusted to 1,343,888 shares [15][16][20]. - The company has completed the registration of 1,094,275 shares for the initial grant and 249,613 shares for the reserved grant, with the listing date set for December 27, 2023 [7][9]. Group 2: 2025 Restricted Stock Incentive Plan - The 2025 incentive plan has also been adjusted, with the initial grant price set at 13.27 yuan per share, which was later adjusted to 10.21 yuan per share due to similar corporate actions [19][20]. - The total number of restricted stocks for the initial grant was adjusted to 1,821,300 shares, reflecting the company's capital reserve conversion and stock dividend distribution [20]. - The company has confirmed that the proposed recipients of the 2025 incentive plan meet all legal and regulatory requirements, with no objections raised during the public disclosure period [12][13].

Investment Rating - The report provides a positive investment rating for the health supplement industry, particularly highlighting the growth potential of the HMB segment and the overall market expansion [4][28]. Core Insights - The report emphasizes that the global dietary supplement industry is experiencing continuous expansion, with the market size expected to approach $200 billion by 2025, driven by increasing health awareness among consumers [28]. - The company, as the largest global supplier of HMB, is well-positioned to benefit from the growing demand for muscle health products, with a projected revenue increase of 22.8% in 2024 [49][60]. - The report also notes the company's strong partnerships with major clients like Abbott, which significantly contribute to its revenue, particularly in the HMB segment [55][111]. Financial Performance - The company achieved a revenue of 1.0 billion yuan in 2024, reflecting a year-on-year growth of 12.3% [3][7]. - The net profit attributable to shareholders reached 174.4 million yuan in 2024, with a compound annual growth rate (CAGR) of 16.7% from 2021 to 2024 [7][21]. - The gross margin improved to 43.5% in 2024, while the net margin slightly decreased to 17.5% due to a minor increase in expenses [21][22]. Revenue Breakdown - In 2024, the revenue from nutritional raw materials and formulations was 6.5 billion yuan and 3.5 billion yuan, respectively, accounting for 64.6% and 35.1% of total revenue [12][96]. - The HMB segment generated 2.93 billion yuan in revenue in 2024, representing 45.3% of the nutritional raw materials revenue [49][85]. - The company’s international sales are significant, with the U.S. accounting for 30.6% of revenue, indicating a strong presence in overseas markets [15]. Market Trends - The global sports nutrition market is projected to grow at a CAGR of 4.5% from 2020 to 2026, with HMB being a key ingredient driving this growth [33][35]. - The joint health supplement market, including glucosamine and chondroitin sulfate, is expected to maintain a steady growth rate of 5.8% from 2020 to 2027, supported by an aging population [39][41]. - The report highlights the increasing penetration of contract manufacturing in the health supplement industry, with a market size exceeding 100 billion yuan [45]. Production Capacity and Utilization - The company’s production capacity for HMB, glucosamine, and chondroitin sulfate is expected to exceed 90% utilization in 2024, indicating strong demand [117]. - The company plans to invest 210 million yuan to expand its production capacity for HMB and other nutritional raw materials, which will enhance its ability to meet growing market demands [117][120].

Group 1 - The food and beverage sector experienced a decline in performance and stock prices in the first half of 2025, with revenue growth of 2.46% and net profit growth of 0.28%, both significantly lower than the previous year [1][16] - The food and beverage sector's stock price fell by 7.33%, ranking second to last among 31 sectors in the first half of 2025, with the liquor segment being particularly hard hit [1][26] - The current PE valuation percentile for the food and beverage sector is at 7.26%, indicating a historical low [1][35] Group 2 - Macroeconomic policies aimed at boosting domestic consumption are crucial for achieving GDP growth targets, with a comprehensive consumption promotion plan issued on March 16, 2025 [2] - The Chinese consumption market is witnessing three concurrent trends: rational consumption, emotional consumption, and health-oriented consumption, which are driving changes in the industry [2] - Rational consumption is characterized by a preference for high-quality, low-cost products, leading to rapid growth in discount retail [2] Group 3 - In the beverage segment, energy drinks are experiencing significant growth, with a projected compound annual growth rate of 10.2% from 2024 to 2029 [3] - The snack food sector is seeing growth driven by channel restructuring and product innovation, with new retail formats like bulk snack stores emerging [3] - The health supplement industry is benefiting from increased health awareness among consumers, leading to structural investment opportunities [3] Group 4 - The beer sector is expected to see marginal improvements due to cost reductions and a recovery in mid-to-high-end beer demand driven by restaurant recovery and sports events [8] - The condiment sector is benefiting from continued cost advantages and a growing demand for compound and health-oriented products [8] - The dairy sector is showing signs of cost stabilization, with a potential easing of price wars expected in 2025 [8] Group 5 - The liquor industry is currently in a phase of inventory destocking, with performance under pressure and a prolonged destocking cycle anticipated due to recent "alcohol bans" [8] - The performance of mid-range and mass-market liquor is expected to be relatively better, as they gain favor in a rational consumption environment [8] - The liquor sector is projected to be in a bottoming phase, with low valuations and high dividends providing strong support for stock prices [8]

Group 1 - The report emphasizes the reconstruction of investment paradigms in the food and beverage sector, driven by new consumption trends that focus on emotional value, health, and technological innovation [1][14][30] - The new consumption paradigm is characterized by a shift from traditional consumption frameworks to a model that prioritizes innovative supply and new demand creation through quality offerings [1][14][35] - The report identifies three main consumption trends: rational quality consumption, emotional value self-consumption, and technological iteration innovation [1][14][30] Group 2 - The analysis of sub-sectors indicates that traditional leaders in beer, dairy, and condiments should be evaluated through traditional consumption frameworks, while new consumption-driven sectors like snacks, tea drinks, and health products require a bottom-up approach to identify explosive changes [2][35] - In the snack sector, companies with category dividends and new channel expansions are expected to perform well, with projected revenue growth rates for various companies in Q2 2025 [4][36] - The soft drink sector shows differentiated performance across segments, with energy drinks and ready-to-drink tea expected to grow, while traditional segments face challenges [4][37] Group 3 - The dairy sector is anticipated to have stable revenue in Q2 2025, with a focus on profit elasticity once raw milk prices stabilize [4][38] - The tea drink market is experiencing high growth driven by the delivery battle, with key players like Mixue Group and Cha Bai Dao expected to thrive in the mid-price segment [4][41] - The health product sector is seeing a concentration in the B-end market, while the C-end market requires attention to high-growth single products [4][39] Group 4 - Investment recommendations include companies that align with new consumption trends, such as Wei Long, Yili, Wanchen Group, and others, indicating a focus on long-term growth opportunities despite short-term adjustments [6][35] - The report highlights the importance of supply chain optimization and product innovation for brands to remain competitive in the evolving retail landscape [30][33]

Core Viewpoint - The company, Jiaoda Onlly, has faced a dramatic turn of events following its high-profile media briefing on July 9, where it accused former executives of financial misconduct. Shortly after, the China Securities Regulatory Commission (CSRC) initiated an investigation into the company for alleged violations of information disclosure laws, highlighting a complex web of capital mismanagement and governance issues [1][3][6]. Group 1: Company Actions and Responses - On July 9, Jiaoda Onlly held a media briefing to announce that former executives allegedly misappropriated company funds through fraudulent insurance transactions, claiming to have gathered evidence and reported the matter to the police [1]. - The chairman, Ji Min, revealed that the police had issued a "no case" notice, indicating that the evidence may be insufficient for criminal charges, which raised questions about the company's communication strategy [2]. - Following the police's decision, the CSRC announced on July 11 that it would investigate the company for potential information disclosure violations, suggesting that the company's earlier disclosures may have been selective and misleading [3]. Group 2: Allegations and Investigations - The core issue revolves around the alleged "insurance purchase and cancellation" scheme, which is seen as a covert method for transferring funds illegally [4][5]. - Specific operations involved creating fictitious or overpriced insurance needs, quickly canceling policies to cash out, and redirecting funds to accounts controlled by former executives, raising concerns about the adequacy of evidence for criminal prosecution [5]. - The CSRC's investigation shifts the focus from whether former executives committed misappropriation to whether the current management acted in compliance with disclosure regulations [6]. Group 3: Financial Implications and Risks - The company faces significant challenges in pursuing civil recovery of losses due to the police's refusal to file a case, which complicates the burden of proof in civil litigation [6]. - If the CSRC finds the company guilty of disclosure violations, it could face penalties including fines up to 10 million yuan, and responsible executives could face fines and market bans [6]. - The company's financial health is precarious, with a reported 95% drop in net profit for 2023 and continued losses in early 2024, raising concerns about its ability to recover and maintain compliance with regulatory standards [6][7].